

# HIV-1 Env gp120 C2V5 Potential N-Linked Glycosylation Site(s) (PNGs) Variations and Amino Acid Length Polymorphisms among Infected Family Members

Duri Kerina<sup>1\*</sup>, Felicity Zvanyadza Gumbo<sup>2</sup>, Knut Ivans Kristiansen<sup>3</sup>, Munyaradzi Paul Mapingure<sup>4</sup>, Simba Rusakaniko<sup>5</sup>, Mike Zvavahera Chirenje<sup>6</sup>, Babill Stray-Pedersen<sup>4</sup>, Fredrik Müller<sup>3</sup>

<sup>1</sup>Department of Immunology, University of Zimbabwe, Harare, Zimbabwe; <sup>2</sup>Department of Pediatrics and Child Health, University of Zimbabwe, Harare, Zimbabwe; <sup>3</sup> Department of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway; <sup>4</sup>Letten Foundation Research Centre, Harare, Zimbabwe; <sup>5</sup>Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe; <sup>6</sup>Department of Obstetrics and Gynecology, University of Zimbabwe, Harare, Zimbabwe; <sup>7</sup> Division of Women and Children, Oslo University Hospital, Rikshospitalet and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Email: <sup>\*</sup>tkduri@yahoo.co.uk,

Received August 2<sup>nd</sup>, 2011; revised September 6<sup>th</sup>, 2011; accepted September 13<sup>th</sup>, 2011.

# ABSTRACT

**Objective:** To ascertain the role of HIV-1 gp120 env PNGs variations and sequence length polymorphism following transmission events as possible supporting forensic evidence to determine directionality of HIV transmission. Method: An observational study of HIV-1 infected family members, where median and range values of the amino acid lengths and PNGs for the genotyped C2V5 region were calculated. Wilcoxon rank-sum test was used to determine differences in these parameters between different family members. **Results:** For heterosexual transmission, two mothers had longer C3 sequences relative to that of their spouses; p = 0.006 and p = 0.025 whilst the opposite was observed for one mother, p = 0.028. No clear trends were observed for PNGs. In three families, index children had longer C2V5 amino acid sequences compared to their mothers; p = 0.013, 0.040 and 0.043. Second siblings' V4 and V5 sequences were generally shorter relative to the maternal ones; p = 0.039 and 0.028, respectively. Generally adults had longer V3 amino acid sequences compared to the children; p = 0.018. Similar trends were also observed regarding PNGs within the entire C2V5 region, C3 and V4 sub-regions; p = 0.0025, 0.005 and 0.008, respectively. First siblings' C2V5 and C3 sequence lengths were significantly longer relative to those of the second siblings; p = 0.005 and 0.007, respectively. Conclusion: Our results are suggestive that HIV-1 env C2V5 amino acid length polymorphism and PNGs tend to increase with age and HIV disease progression. Though sensitive and should be cautiously handled, it is tempting to propose the directionality of the HIV transmission events with respect to C3 sequence length polymorphisms. Correlating HIV-1 env C2V5 amino acid length polymorphism and age of infection may be the first step towards a possible valuable piece of forensic evidence which may be useful in criminalisation of willful HIV infections. However, bigger studies are warranted to substantiate the authenticity of this potentially useful application.

Keywords: HIV-1 Env120 C2V5, Glycosylation, Amino Acid Length Polymorphism, Parent to Child Transmission

# 1. Introduction

Human immunodeficiency virus type 1 envelope glycoprotein 120 (HIV-1 env gp120) is composed of relatively conserved constant (C) C1 to C5 and variable (V) V1 to V5 regions [1]. It is ranked one of the most heavily glycosylated proteins known in nature with N-linked glycans constituting over 55% of its molecular weight [2,3]. This extensive glycosylation is known to play an important role in evasion of the host immune response by masking key neutralization epitopes and presentation of the glycosylated env (glycan shield) to the immune system as "self" [4-9]. Under host immune response or antiretroviral therapy selection pressures, it is postulated that HIV-1 evolves towards a denser glycan shield [10], an observation also supported by others [11-13]. According to this hypothesis, shorter variant with fewer glycans are expected during earlier time points of infection whilst longer V1 - V5 forms with more glycans are expected to evolve at a later stage in response to prolonged immune pressures [14,15], making it possible to assign the directionality of transmission.

Regardless of the HIV-1 subtype, the number of potential N-glycosylation site(s) (PNGs) within the gp120 env gene (env) is conserved at about 25 [10,16]. However, there is a tendency for heterosexually and perinatally transmitted viruses to have shorter env variable loops and fewer PNGs [14,17-21]. Changes in the number of PNGs and env gp120 V1-V5 amino acid lengths have been associated with striking a balance between transmission competence and resistance to immune challenges [14,21-23]. Whilst glycosylation within the HIV-1 env V3 loop may change the viral co-receptor usage [24], loss of PNGs within the V4 region has been correlated with dementia [25]. Intra-host HIV-1 PNGs diversity varies, with some PNGs being evolutionarily conserved while others may be present in some hosts but absent in others and some may even appear or disappear during the course of infection [3,10]. HIV-1 subtype B env gp120 V4 loop has been shown to appear as swarms of heterogeneous N-linked glycosylation variants due to mutations, insertions and deletions (indels) which consequently affect amino acid sequence lengths and PNGs distribution patterns [26.27].

Although glycosylation of HIV-1 remains the main obstacle to viral control and eradication, it is possible to exploit the protective glycosylation profiles of gp120 against the virus for the development of an env based vaccine candidate [26]. For this reason, understanding glycan shield glycosylation patterns is critical. There is a paucity of data in Zimbabwe regarding the number and distribution patterns of HIV-1 subtype C gp120 env PNGs and sequence length polymorphisms in adults following heterosexual transmission, let alone in vertically infected children. More so, gp120 env characteristics of the unusually prolonged survival of HIV-1 infected but drug naïve pediatric patients are not well documented. Our study population of HIV-1 infected family members provided a unique opportunity to investigate gp120 env PNGs patterns and amino acid sequence lengths polymorphisms following heterosexual and subsequent parent to child transmission (PTCT) events, a unique scenario that has not been reported elsewhere.

#### 2. Materials and Method

#### **Study Population and Procedures**

Described are HIV-1 transmission events of close contacts of whom the time and directionality of vertical transmission was known but unknown for heterosexual transmission. The unit of analysis was a family. Four families were willing to participate in our study. HIV-1 infected families labeled 205, 366, 375 and 567 consisted of biological parent(s) and children, index child sibling) sibling (older/first and index child's (younger/second sibling), constituted the study population. The index child was defined as the first child to be recruited into our study. Two families comprised each of both parents and a respective biological index child. The other two families were composed of parent(s) and two subsequent biological children, the first and second siblings. For Family 567 the father figure was missing as he was working in another regional country. Each family member was HIV-1 infected and none had received antiretroviral therapy at the time of sample collection.

Consent was obtained from the respective pregnant mother of each family participating in the national PMTCT programme in Harare peri-urban mother and child clinics that were known to be HIV-1 positive at 36 weeks gestation. Spouses also consented to participate in the family HIV genetic study. Similar recruitment and procedures were followed as previously described [27]. All the infants were breast fed for at least nine months. First siblings' blood samples were collected at  $60 \pm 10$ months of age as there were insufficient sample volumes from their respective first available HIV-1 positive samples. In cases of second siblings the first available HIV-1 positive samples were genotyped and sampling time was at about  $15 \pm 3$  months of age. Nucleic acid extraction, PCR amplification, cloning and DNA sequencing methods for the HIV-1 env gp120 C2V5 region were done as previously described and so was HIV-1 subtype determination[28].

#### **3. Data Analysis**

Data were entered and analysed using Stata version 10. The number and distribution of PNGS including C2V5 sequence length polymorphisms were determined for both the parent(s) and children. To compare the sequences' lengths and number of PNGs between family members, a non parametric Wilcoxon rank-sum (Mann-Whitney) test was used. Tests of statistical significance included the 95% confidence interval of relative risks and two sided p-values. Similar analysis was done after stratifying the study population by age and gender for both heterosexual and vertical transmission events. Indels assessment along the sequences was done manually. The 520 base pair nucleotide sequences were translated to amino acid sequence using the Gene Doc program. The amino acid sequences in their fasta formats were entered into a glycosylation analysis site:

http://www.hiv.lanl.gov/content/hiv-db/GLYCOSITE/gly cosite where PNGs were marked and counted. Variations in the number and location of PNGs within the entire C2V5 region and sub-regions were analysed. Median and range values of sequence lengths and PNGs were calculated for each family member as previously described by others [14].

# 4. Ethical Consideration

The study was approved by the Medical Research Council of Zimbabwe (MRCZ) and the Ethical Review Committee in Norway. Written consent to participate in the HIV-1 genetic research study was obtained from the parent(s) who also consented on behalf of their minors. Study participants were free to discontinue at any time without any prejudice. Parents also consented to have their blood samples and those of their children to be used for other future HIV related research studies.

# 5. Results

#### 5.1. Characteristics of the Four Families

Three of the four couples were in a monogamous marriage except for Mother 375 who was in a polygamous relationship. All parents had at least seven years in school and were of low economic status. Mean age of the mothers and their spouses were 34.8 years  $\pm$  3.2 years and 38 years  $\pm$  2 years, respectively.

# **5.2. HIV Infections**

Parents of the four families were HIV-1 positive at enrolment but did not know when and how they got infected. Mode of HIV-1 acquisition was most likely heterosexually as none mentioned any history of blood transfusion, drug abuse or homosexuality except for mother 366 who had a history of blood transfusion hence it could not be substantiated whether she got infected heterosexually or through blood transfusion. Index children of families 366, 375 and 567 and second siblings of families 205 and 567 were HIV-1 DNA PCR negative at delivery and six weeks postpartum but later got infected through breastfeeding. Index child 205 was HIV-1 DNA PCR negative at delivery. However, he did not turn up for his 6 week postpartum visit hence his time of infection was not definite.

## 5.3. Global Analysis of Families' C2V5 Sub-Regions Nucleotide Sequences

Consistent feature of families sequence analysis showed the highest variation within the *env* gp120 V4 and V5 and interestingly also within the C3 sub-regions. Indels characterized the genetic diversity of these three sub-regions. In contrast amino acid substitutions constituted the main cause of variability within the constant domains C2, C4 and to a lesser extent V3 region, see **Figure 1**. Of note was a 12 base pair nucleotide insertion observed in Family 366 Mother-Infant pair viral sequences that was absent in the purported father's HIV sequence.

## 5.4. Glycosylation Patterns and Amino Acid Lengths of the Variable Loops, V3-V5

Of the variable regions, V3 was relatively conserved regardless of family member age or sex with no insertions, deletions or shifts in PNGs that characterized V4 and V5 domains. Families 205, 366 and 375 V3 amino acid lengths were all 35, see **Tables 1-3**. Contrary, most sequences of 567 family members were of 33 amino acids in length; consequently they had the least number of PNGs. Despite having the optimal amino acids length within the V3 region, Family 375 had a just single PNGs, see **Tables 1-6**. Remarkably was the presence of the conserved GPGQ motif within the V3 crown of all family members' viral sequences that was preserved following both heterosexual and vertical transmission events. On the contrary, 2/5 of Mother 366 HIV-1 clones had GPGR motif instead.

V4 region showed extensive amino acid length polymorphism and PNGs variation ranging from median (range) 28(24 - 35) and 3(2 - 6) respectively, see **Tables 1** and **6**. There were numerous deletions in this region resulting in variants with different V4 region amino acid length polymorphisms as shown by sequence lengths of fathers 205 and 375 including Mother 567 and to some extent Mother 366. The first two PNGs had more fixed locations in the distribution whilst the other two were randomly distributed. Interestingly, Father 205 lost a PNGs resulting in his major HIV-1 variants having just 3 PNGs. Insertions within Mother 366 HIV-1 sequences resulted in her gaining one more PNGs. Of note was the loss of the first PNGs within the V4 region observed in 3/4 of the index children, see Figure 1. V5 region PNGs varied from median (range) 2 (1 - 3) between families, with Family 205 HIV-1 variants having an average of 3 per family member whilst just one PNGs was a common observation with Family 567.


# 5.5. Glycosylation Patterns and Amino Acid Lengths of the Constant Regions

#### 5.5.1. Heterosexual Transmission

There were no significant gender differences with respect to amino acid lengths between fathers and mothers for the entire C2V5 length, 207 (199 - 215); 208 (198 - 216), p = 0.734. However, after stratifying by sub-regions, there was a general tendency for mothers of families 366 and 375 to have longer C3 region amino acid lengths

#### HIV-1 Env gp120 C2V5 Potential N-Linked Glycosylation Site(s) (PNGs) Variations and Amino Acid Length Polymorphisms among Infected Family Members

HIV subtype C Env C2 -V5 Regions




HIV subtype C Env C2 -V5 Regions

|  | V3 Loop   |  |   |
|--|---|--|---|
| CONS V3 Loc<br>205_F_C<br>A<br>D<br>M_A<br>B<br>D<br>1STB<br>2NDA<br>B | CT R P N N N T R K S I R I GP GQ T F YA T G DI I G DI R Q A H C   . V   | Length<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35 | PNGs<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2 |
| 366_F_A<br>_B<br>_C<br>_D<br>M_E<br>_C<br>1ST_B<br>_D                  | G . | 35<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35                             | 1<br>1<br>0<br>2<br>2<br>2<br>2<br>2  |
| 375_F_A<br>_C<br>_D<br>M_A<br>_B<br>_D<br>_E<br>1ST_D                  | G V V   | 35<br>35<br>35<br>35<br>35<br>35<br>35<br>35<br>35                             | 1<br>1<br>1<br>1<br>1<br>1<br>1   |
| 567_М_А<br>_C<br>_D<br>1ST C<br>_D<br>2ND_В<br>2ND_C                   |   | 33<br>35<br>33<br>33<br>33<br>33<br>33<br>33                                   | 1<br>2<br>1<br>1<br>1<br>1  |

Copyright © 2011 SciRes.

#### HIV-1 Env gp120 C2V5 Potential N-Linked Glycosylation Site(s) (PNGs) Variations and Amino Acid Length Polymorphisms among Infected Family Members

HIV subtype C Env C2 -V5 Regions



#### HIV subtype C Env C2 -V5 Regions

|   | V4 Loop  |  |
|---|--|--|
| CONS C<br>205FA C<br>205FA A<br>205FA D<br>205MO A<br>205MO B<br>205MO D<br>205 1ST B<br>205 2ND A<br>205 2ND A | C N T S T V N S T I L P C [22] 4   . . . D . T T - - - - - Y N S T I L P C [22] 4   . . . D . . T T - - - - Y T K N S T I L Q C [23] 3   . . T N . S T - - - - Y - K K K K . |  |
| 366 FA A<br>366 FA B<br>366 FA C<br>366 FA D<br>366 MO E<br>366 MO C<br>366 1ST B<br>366 1ST D                  | .        |  |
| 375 FA A<br>375 FA C<br>375 FA D<br>375 MO A<br>375 MO B<br>375 MO D<br>375 MO E<br>375 1ST D                   | .        |  |
| 567MO A<br>567Mo C<br>567Mo D<br>567 1ST C<br>567 1ST D<br>567 2ND B<br>567 2ND C                               | .        |  |

5

HIV subtype C Env C2 -V5 Regions

| C4      |  |      |
|---------|--|------|
| ONS     | RIKQIINMWQE V G RAMYAPPIAG <mark>N</mark> IT C K S <mark>N</mark> IT G L L L | 36 2 |
| 5FA C   | G  | 36 2 |
| 5Fa A   | · · · · · · · · · · · · · · · · · · ·  | 36 2 |
| 5FA D   | · · · · · · · · · · · · · · · · · · ·  | 36 2 |
| 5Mo A   |  | 36 2 |
| 5MO B   |  | 36 2 |
| 5MO D   |  | 36 2 |
| 5 1ST B |  | 36 2 |
| 5 2ND A |  | 36 2 |
| 5 2nd B |  | 36 2 |
| 6 FA A  |  | 36 2 |
| 6 FA B  |  | 36 2 |
| 6 FA C  | · · · · · · · · · · · · · · · · · · ·  | 36 2 |
| 6 FA D  |  | 36 2 |
| 5 MO E  | G  | 36 2 |
| 3 MO C  | · · · · · · · · · · · · · · · · · · ·  | 36 2 |
| 6 1ST B | K  | 36 2 |
| 6 1ST D | К  | 36 2 |
| 5 FA A  | · · · · · · · · · · · · · · · · · · ·  | 36 2 |
| 5 FA C  |  | 36 2 |
| 5 FA D  |  | 36 2 |
| 5 MO A  |  | 36 2 |
| 5 MO B  |  | 36 2 |
| 5 MO D  |  | 36 2 |
| 5MO E   |  | 36 2 |
| 5 1ST D |  | 36 2 |
| 7MO A   |  |      |
|         |  | 36 2 |
| 7Mo C   |  | 36 2 |
| 7Mo D   | · · · · · · · · · · · · · · · · · · ·  | 36 2 |
| 7 1ST C | · · · · · · V · · · · · K · · · · · · ·                                      | 36 2 |
| 7 1ST D | · · · · · · V · · · · · K · · · · · · ·                                      | 36 2 |
| 7 2ND B | V K V <mark>.</mark> R. <mark>.</mark>                                       | 36 2 |
| 7 2ND C | V K  | 36 2 |

HIV subtype C Env C2 -V5 Regions

| V5 Loop   |   |   |   |   |   |    |   |   |   |   |   |   |   |
|-----------|---|---|---|---|---|----|---|---|---|---|---|---|---|
| CONS      | Т | R | D | G | G | -  | - | - | ÷ | Κ | Ν | Ν | Т |
| 205FA C   | Т | R | D | G | G | -  | - | - | G | Ν | Ν | G |   |
| 205Fa A   |   |   |   |   |   | Ν  | Ν | Ν | S | Т | - | - |   |
| 205FA D   |   |   |   |   |   | -  | - | - |   |   |   |   |   |
| 205Mo A   |   |   |   |   |   | Ν  | Ν | Ν | S | Т | - | - |   |
| 205MO B   |   |   |   |   |   | Ν  | Ν | Ν | S | Т | - | - |   |
| 205MO D   |   |   |   |   |   | Ν  | Ν | Ν | S | Т | - | - |   |
| 205 1ST B |   |   |   |   |   | Ν  | Ν | Т | Е | Т |   |   |   |
| 205 2ND A |   |   |   |   |   | Κ  | Ν | S | Т | - | - | - |   |
| 205 2nd B |   |   |   |   |   | Ν  | Ν | Ν | S | Т | - | - |   |
| 366 FA A  | Е | С |   |   |   | Ν  | Q | Т | Ν | - | - | - |   |
| 366 FA B  |   |   |   |   | D | G  | Ν | D | Т | Е | - | - |   |
| 366 FA C  |   |   |   |   | D | G  | Ν | D | Т | Е | - | - |   |
| 366 FA D  | Е |   |   |   |   | Ν  | Q | Т | Ν | - | - | - |   |
| 366 MO E  | V |   |   |   |   | Κ  | Ν | Ν | Т |   | - | - |   |
| 366 MO C  | V |   |   |   | · | Ν  | Ν | Ν | Т |   | - | - |   |
| 366 1ST B | V |   |   |   | · | Ν  | Ν | Ν | - | D | - | - |   |
| 366 1ST D | V | ÷ | · | · | · | Ν  | Ν | Ν | - | D | - | - |   |
| 375 FA A  | Е | С | ÷ | · | · | Ν  | Q | Т | Ν | - | - | - |   |
| 375 FA C  | · | ÷ | · | · | · | Ν  | Ν | S | S | · | · | Т |   |
| 375 FA D  |   | · |   | · | · | Ν  | Ν | S | S | ÷ | · | Т |   |
| 375 MO A  |   | W |   | · | Т | S  | S | D | Ν | G | S | D |   |
| 375 MO B  | · | W |   | · | т | s  | s | D | Ν | G | S | D |   |
| 375 MO D  |   | W |   | · | Т | S  | S | D | Ν | G | S | D |   |
| 375MO E   |   | W |   | · | Т | S  | S | D | Ν | G | S | D |   |
| 375 1ST D | S | W |   |   | Κ | G  | - | D | Ν | G | Т | D |   |
| 567MO A   |   |   |   | · |   | 1  | Е | Т | S | D | - | - |   |
| 567Mo C   |   |   |   |   |   | I. | Е | Т | S | D | - | - |   |
| 567Mo D   |   |   |   |   |   | Ν  | Ν | Ν | S | Т | - | - |   |
| 567 1ST C |   |   |   |   |   | -  | - | Т | S |   | S | - |   |
| 567 1ST D |   |   |   |   |   | -  | - | Т | S |   | S | - |   |
| 567 2ND B |   |   |   |   |   | -  | - | S | D |   | S | А |   |
| 567 2ND C |   |   |   |   | Е | -  | - | S | D |   | - | - |   |

| Pairs                              | C2V5<br>Median (Range)                      | C2<br>Median<br>(Range)           | V3<br>Median<br>(Range)           | C3<br>Median<br>(Range)               | V4<br>Median<br>(Range)               | C4<br>Median<br>(Range)           | V5<br>Median<br>(Range)               |
|------------------------------------|---|-----------------------------------|-----------------------------------|---------------------------------------|---------------------------------------|-----------------------------------|---------------------------------------|
| 205<br>Father<br>Mother<br>P-value | 200 (199 - 202)<br>202 (200 - 203)<br>0.156 | 42 (42 - 42)<br>42 (42 - 42)      | 35 (35 - 35)<br>35 (35 - 35)<br>- | 48 (47 - 49)<br>47 (47 - 47)<br>0.028 | 26 (26 - 26)<br>28 (26 - 29)<br>0.079 | 36 (36 - 36)<br>36 (36 - 36)<br>- | 13 (13 - 14)<br>14 (14 - 14)<br>0.025 |
| 366<br>Father<br>Mother<br>P-value | 211 (210 - 214)<br>214 (213 - 216)<br>0.045 | 42 (42 - 42)<br>42 (42 - 42)      | 35 (35 - 35)<br>35 (35 - 35)<br>- | 49 (49 - 51)<br>54 (54 - 54)<br>0.006 | 34 (33 - 35)<br>32 (30 - 33)<br>0.017 | 36 (36 - 36)<br>36 (36 - 36)<br>- | 15 (15 - 15)<br>16 (15 - 16)<br>0.074 |
| 375<br>Father<br>Mother<br>P-value | 211 (203 - 215)<br>212 (212 - 213)<br>1.000 | 42 (42 - 42)<br>42 (42 - 42)<br>- | 35 (35 - 35)<br>35 (35 - 35)<br>- | 49 (49 - 51)<br>51 (51 - 51)<br>0.025 | 33 (25 - 35)<br>28 (28 - 28)<br>0.178 | 36 (36 - 36)<br>36 (36 - 36)<br>- | 16 (15 - 17)<br>20 (20 - 21)<br>0.012 |
| 567<br>Father<br>Mother<br>P-value | 198 (198 - 200)<br>-                        | 42 (42 - 42)                      | 34 (33 - 35)                      | 48 (47 - 48)                          | 25 (24 - 25)                          | -<br>36 (36 - 36)<br>-            | -<br>14 (14 - 15)<br>-                |

#### Table 1. C2V5 and subregions amino acid (AA) lengths following Heterosexual transmission.

Table 2. C2V5 and sub-regions amino acid (AA) lengths following vertical transmission.

| Pairs   | C2V5<br>Median (Range)  | C2<br>Median<br>(Range)                      | V3<br>Median<br>(Range)  | C3<br>Median<br>(Range)  | V4<br>Median<br>(Range)  | C4<br>Median<br>(Range)                      | V5<br>Median<br>(Range)  |
|---|---|--|--|--|--|--|--|
| 205<br>Mother<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 202 (200 - 203)<br>207 (206 - 207)<br>0.013<br>200 (199-202)<br>0.058   | 42 (42 - 42)<br>42 (42 - 42)<br>42 (42 - 42) | 35 (35 - 35)<br>35 (35 - 35)<br>35 (35 - 35)                   | 47 (47 - 47) 52 (52 - 52) 0.005 48 (47 - 52) 0.264             | 28 (26 - 29)<br>26 (26 - 26)<br>0.079<br>26 (25 - 26)<br>0.039 | 36 (36 - 36)<br>36 (36 - 36)<br>36 (36 - 36) | 14 (14 - 14)<br>16 (15 - 16)<br>0.007<br>13 (12 - 13)<br>0.028 |
| 366<br>Mother<br>1st sibling<br>p-value                           | 214 (213 - 216)<br>216 (216 - 216)<br>0.105                             | 42 (42 - 42)<br>42 (42 - 42)                 | 35 (35 - 35)<br>35 (35 - 35)<br>-                              | 54 (54 - 54)<br>54 (54 - 54)<br>-                              | 32 (30 - 33)<br>32 (32 - 32)<br>1.000                          | 36 (36 - 36)<br>36 (36 - 36)<br>-            | 16 (15 - 16)<br>17 (17 - 17)<br>0.040                          |
| 375<br>Mother<br>1st sibling<br>p-value                           | 212 (212 - 213)<br>209 (209 - 209)<br>0.040                             | 42 (42 - 42)<br>42 (42 - 42)                 | 35 (35 - 35)<br>35 (35 - 35)<br>-                              | 51 (51 - 51)<br>49 (49 - 49)<br>0.014                          | 28 (28 - 28)<br>28 (28 - 28)<br>-                              | 36 (36 - 36)<br>36 (36 - 36)<br>-            | 20 (20 - 21)<br>19 (19 - 19)<br>0.040                          |
| 567<br>Mother<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 198 (198 - 200)<br>201 (201 - 202)<br>0.043<br>201 (198 - 202)<br>0.239 | 42 (42 - 42)<br>42 (42 - 42)<br>42 (42 - 42) | 34 (33 - 35)<br>33 (33 - 33)<br>0.317<br>33 (33 - 33)<br>0.317 | 48 (47 - 48)<br>49 (49 - 49)<br>0.034<br>48 (48 - 49)<br>0.197 | 25 (24 - 25)<br>27 (27 - 27)<br>0.034<br>30 (25 - 30)<br>0.099 | 36 (36 - 36)<br>36 (36 - 36)<br>36 (36 - 36) | 15 (14 - 15)<br>14 (14 - 15)<br>0.456<br>13 (13 - 13)<br>0.034 |

relative to their respective spouses; 49(49-51); 54(54-54), and 49(49 - 51); 51(51 - 51), p=0.006 and 0.025 respectively whilst the opposite was true for Mother 205, see **Table 1**. Mother 375 consistently had lower numbers of PNGs compared to the spouse, yet the opposite was true regarding amino acid lengths. See **Table 2**. No clear trend was observed regarding the number of PNGs

following the 3 heterosexual transmission events. There were also no significant gender differences with respect to PNGs between mothers and fathers 14(9 - 16); 15(12 - 19) p = 0.156. However, for sub-regionV4 fathers tended to have higher PNGs, being significant for heterosexual partners of family 375.5(4 - 6), 3(3 - 3) p = 0.007, see **Table 2**.

| Pairs   | C2V5<br>Median (Range)  | C2<br>Median<br>(Range)                      | V3<br>Median<br>(Range)                           | C3<br>Median<br>(Range)  | V4<br>Median<br>(Range)                               | C4<br>Median<br>(Range)                           | V5<br>Median<br>(Range)  |
|---|---|--|---|--|---|---|--|
| 205<br>Father<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 200 (199 - 202)<br>207 (206 - 207)<br>0.019<br>200 (199 - 202)<br>0.350 | 42 (42 - 42)<br>42 (42 - 42)<br>42 (42 - 42) | 35 (35 - 35)<br>35 (35 - 35)<br>-<br>35 (35 - 35) | 48 (47 - 49)<br>52 (52 - 52)<br>0.013<br>48 (47 - 52)<br>0.439 | 26 (26 - 26)<br>26 (26 - 26)<br>26 (25 - 26)<br>0.127 | 36 (36 - 36)<br>36 (36 - 36)<br>-<br>36 (36 - 36) | 13 (13 - 14)<br>16 (15 - 16)<br>0.017<br>13 (12 - 13)<br>0.617 |
| 366<br>Father<br>1st sibling<br>p-value                           | 211 (210 - 214)<br>216 (216 - 216)<br>0.057                             | 42 (42 - 42)<br>42 (42 - 42)                 | 35 (35 - 35)<br>35 (35 - 35)                      | 49 (49 - 51)<br>54 (54 - 54)<br>0.046                          | 34 (33 - 35)<br>32 (32 - 32)<br>0.057                 | 36 (36 - 36)<br>36 (36 - 36)<br>-                 | 15 (15 - 15)<br>17 (17 - 17)<br>0.025                          |
| 375<br>Father<br>1st sibling<br>p-value                           | 211 (203 - 215)<br>209 (209 - 209)<br>1.000                             | 42 (42 - 42)<br>42 (42 - 42)                 | 35 (35 - 35)<br>35 (35 - 35)<br>-                 | 49 (49 - 51)<br>49 (49 - 49)<br>0.480                          | 33 (25 - 35)<br>28 (28 - 28)<br>0.340                 | 36 (36 - 36)<br>36 (36 - 36)<br>-                 | 16 (15 - 17)<br>19 (19 - 19)<br>0.057                          |
| 567<br>Father<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 201 (201 - 202)<br>0.043<br>201 (198 - 202)<br>0.239                    | 42 (42 - 42)<br>42 (42 - 42)                 | 33 (33 - 33)<br>0.317<br>33 (33 - 33)<br>0.317    | 49 (49 - 49)<br>0.034<br>48 (48 - 49)<br>0.197                 | 27 (27 - 27)<br>0.034<br>30 (25 - 30)<br>0.099        | 36 (36 - 36)<br>36 (36 - 36)                      | 14 (14 - 15)<br>0.456<br>13 (13 - 13)<br>0.034                 |

Table 3. C2V5 and sub-regions amino acid (AA) lengths variations following PTC transmission.

Table 4. Heterosexual patterns following transmission (PNGS).

| Pairs                              | C2V5<br>Median<br>(Range)             | C2<br>Median<br>(Range)         | V3<br>Median<br>(Range)         | C3<br>Median<br>(Range)         | V4<br>Median<br>(Range)         | C4<br>Median<br>(Range)         | V5<br>Median<br>(Range)         |
|------------------------------------|---------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| 205<br>Father<br>Mother<br>p-value | 13 (12 - 15)<br>16 (15 - 16)<br>0.014 | 3 (3 - 3)<br>3 (3 - 3)<br>-     | 2 (1 - 2)<br>2 (1 - 2)<br>0.371 | 3 (2 - 3)<br>3 (3 - 3)<br>0.091 | 3 (3 - 3)<br>3 (3 - 3)          | 2 (2 - 2)<br>2 (2 - 2)          | 1 (1 - 2)<br>3 (3 - 3)<br>0.006 |
| 366<br>Father<br>Mother<br>p-value | 16 (14 - 19)<br>15 (14 - 16)<br>0.379 | 3 (3 - 3)<br>2 (2 - 2)<br>0.005 | 1 (0 - 1)<br>2 (2 - 2)<br>0.006 | 3 (3 - 4)<br>3 (3 - 4)<br>0.866 | 5 (4 - 6)<br>4 (3 - 5)<br>0.302 | 2 (1 - 2)<br>2 (2 - 2)<br>0.264 | 3 (2 - 3)<br>2 (1 - 2)<br>0.058 |
| 375<br>Father<br>Mother<br>p-value | 16 (15 - 18)<br>13 (13 - 13)<br>0.007 | 3 (3 - 3)<br>3 (3 - 3)<br>-     | 1 (1 - 1)<br>1 (1 - 1)<br>-     | 3 (3 - 4)<br>2 (2 - 2)<br>0.006 | 5 (4 - 6)<br>3 (3 - 3)<br>0.007 | 2 (2 - 2)<br>2 (2 - 2)          | 2 (2 - 2)<br>2 (2 - 2)          |
| 567<br>Father<br>Mother<br>p-value | 10 (9 - 11)                           | 3 (3 - 3)                       | 1 (1 - 2)                       | 1 (1 - 3)                       | 3 (3 - 3)                       | 0 (0 - 0)                       | -<br>1 (1 - 1)<br>-             |

C2 and C4 regions sequence lengths were exactly the same for all families" heterosexual partners but differed with respect to C3, V4 and V5 sub-regions. Applying the postulated hypothesis to C3 and to a lesser extent V5 sub-region sequence lengths [14], it is tantamount to tempting to propose the direction of heterosexual transmission, a very sensitive issue and should be handled carefully. A male to female (MTF) heterosexual transmission was suspected for family 205 with the father probably infecting his wife whilst female to male (FTM)

transmission events were possible for families 366 and 375. Interestingly, though not statistically significant, an exact opposite trend was observed for the V4 variable region, see **Table 1**.

### 5.5.2. PTCT and Sequence Lengths and PNGs

There were no significant V4 region amino acid lengths differences with respect to the C2, V3 and to some extent C4 sub-regions between mothers and first siblings. However, for the entire C2V5 region there was a tendency

| Pairs   | C2V5<br>Median<br>(Range)                                      | C2<br>Median<br>(Range)                      | V3<br>Median<br>(Range)                               | C3<br>Median<br>(Range)                               | V4<br>Median<br>(Range)                               | C4<br>Median<br>(Range)                               | V5<br>Median<br>(Range)                               |
|---|--|--|---|---|---|---|---|
| 205<br>Mother<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 16 (15 - 16)<br>11 (10 - 13)<br>0.010<br>14 (12 - 16)<br>0.080 | 3 (3 - 3)<br>2 (2 - 2)<br>0.005<br>3 (3 - 3) | 2 (1 - 2)<br>1 (1 - 2)<br>0.120<br>2 (1 - 2)<br>0.866 | 3 (3 - 3)<br>2 (1 - 2)<br>0.007<br>3 (1 - 3)<br>0.264 | 3 (3 - 3)<br>3 (3 - 3)<br>-<br>3 (2 - 3)<br>0.264     | 2 (2 - 2)<br>2 (2 - 2)<br>2 (1 - 2)<br>0.264          | 3 (3 - 3)<br>2 (1 - 2)<br>0.007<br>2 (2 - 3)<br>0.025 |
| 366<br>Mother<br>1st sibling<br>p-value                           | 15 (14 - 16)<br>14 (13 - 15)<br>0.320                          | 2 (2 - 2)<br>3 (2 - 3)<br>0.114              | 2 (2 - 2)<br>2 (2 - 2)                                | 3 (3 - 4)<br>3 (3 - 3)<br>0.527                       | 4 (3 - 5)<br>4 (3 - 4)<br>0.306                       | 2 (2 - 2)<br>2 (2 - 2)                                | 2 (1 - 2)<br>1 (1 - 1)<br>0.180                       |
| 375<br>Mother<br>1st sibling<br>p-value                           | 13 (13 - 13)<br>12 (11 - 13)<br>0.114                          | 3 (3 - 3)<br>3 (3 - 3)<br>-                  | 1 (1 - 1)<br>1 (1 - 1)<br>-                           | 2 (2 - 2)<br>2 (2 - 2)                                | 3 (3 - 3)<br>3 (3 - 3)<br>-                           | 2 (2 - 2)<br>1 (0 - 2)<br>0.114                       | 2 (2 - 2)<br>2 (2 - 2)<br>-                           |
| 567<br>Mother<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 10 (9 - 11)<br>12 (12 - 12)<br>0.037<br>13 (12 - 13)<br>0.046  | 3 (3 - 3)<br>3 (3 - 3)<br>-<br>3 (3 - 3)     | 1 (1 - 2)<br>1 (1 - 1)<br>0.317<br>1 (1 - 1)<br>0.317 | 1 (1 - 3)<br>2 (2 - 2)<br>0.480<br>2 (2 - 2)<br>0.480 | 3 (3 - 3)<br>2 (2 - 2)<br>0.025<br>4 (3 - 4)<br>0.114 | 0 (0 - 0)<br>2 (2 - 2)<br>0.025<br>2 (2 - 2)<br>0.025 | 1 (1 - 1)<br>2 (2 - 2)<br>0.025<br>1 (1 - 1)          |

# Table 5. PNG patterns following transmission.

| Table 6. PNG patterns | following PTC | transmission. |
|-----------------------|---------------|---------------|
|-----------------------|---------------|---------------|

|   |  |  |   | -   |   |  |   |
|---|--|--|---|---|---|--|---|
| Pairs   | C2V5<br>Median<br>(Range)                                      | C2<br>Median<br>(Range)                      | V3<br>Median<br>(Range)                               | C3<br>Median<br>(Range)                               | V4<br>Median<br>(Range)                           | C4<br>Median<br>(Range)                      | V5<br>Median<br>(Range)                               |
| 205<br>Father<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 13 (12 - 15)<br>11 (10 - 13)<br>0.080<br>14 (12 - 16)<br>0.457 | 3 (3 - 3)<br>2 (2 - 2)<br>0.008<br>3 (3 - 3) | 2 (1 - 2)<br>1 (1 - 2)<br>0.495<br>2 (1 - 2)<br>0.495 | 3 (2 - 3)<br>2 (1 - 2)<br>0.061<br>3 (1 - 3)<br>0.739 | 3 (3 - 3)<br>3 (3 - 3)<br>-<br>3 (2 - 3)<br>0.317 | 2 (2 - 2)<br>2 (2 - 2)<br>2 (1 - 2)<br>0.317 | 1 (1 - 2)<br>2 (1 - 2)<br>0.495<br>2 (2 - 3)<br>0.040 |
| 366<br>Father<br>1st sibling<br>p-value                           | 16 (14 - 19)<br>14 (13 - 15)<br>0.240                          | 3 (3 - 3)<br>3 (2 - 3)<br>0.157              | 1 (0 - 1)<br>2 (2 - 2)<br>0.046                       | 3 (3 - 4)<br>3 (3 - 3)<br>0.480                       | 5 (4 - 6)<br>4 (3 - 4)<br>0.134                   | 2 (1 - 2)<br>2 (2 - 2)<br>0.480              | 3 (2 - 3)<br>1 (1 - 1)<br>0.053                       |
| 375<br>Father<br>1st sibling<br>p-value                           | 16 (15 - 18)<br>12 (11 - 13)<br>0.060                          | 3 (3 - 3)<br>3 (3 - 3)<br>-                  | 1 (1 - 1)<br>1 (1 - 1)<br>-                           | 3 (3 - 4)<br>2 (2 - 2)<br>0.046                       | 5 (4 - 6)<br>3 (3 - 3)<br>0.057                   | 2 (2 - 2)<br>1 (0 - 2)<br>0.157              | 2 (2 - 2)<br>2 (2 - 2)                                |
| 567<br>Father<br>1st sibling<br>p-value<br>2nd Sibling<br>p-value | 12 (12 - 12)<br>0.037<br>13 (12 - 13)<br>0.046                 | 3 (3 - 3)<br>3 (3 - 3)                       | 1 (1 - 1)<br>0.317<br>1 (1 - 1)<br>0.317              | 2 (2 - 2)<br>0.480<br>2 (2 - 2)<br>0.480              | 2 (2 - 2)<br>0.025<br>4 (3 - 4)<br>0.114          | 2 (2 - 2)<br>0.025<br>2 (2 - 2)<br>0.025     | 2 (2 - 2)<br>0.025<br>1 (1 - 1)                       |

for the index children to have longer amino acid lengths compared to the mothers p = 0.013, 0.040 and 0.043 for families 205, 375 and 567 respectively, see Table 2. Differences were also observed within the V5 sub-region with p values =0.007, 0.040, 0.040 and 0.456 for Families 205, 366, 375 and 567 respectively, but without any clear trend. Family 205 second siblings' V4 and V5 sub-regions amino acid lengths were both significantly shorter relative to the maternal ones; p=0.039 and 0.028 respectively. Similar observations were also noted for 567 second sibling sequences which were significantly shorter relative to maternal ones p=0.034. Significant differences were also observed in the C3 region but with no clear trends. See Table 2. Interestingly a similar trend like the one observed in the mothers with first siblings was also observed with paternal sequences with respect to the C2V5, C3, and V5 regions. However, there were no differences in sequence lengths between paternal ones and those from second sibling, see Table 3. There was a tendency for parents to have longer amino acid lengths for the regions C2V5 and V3 being; 208(198 - 216); 205 (198 - 216): p = 0.138 and 35(33 - 35); 34(33 - 35): p = 0.018. Following stratification by age, there was also a tendency for parents to have denser glycans within the C2V5, C3 and V4 regions which were 14(9 - 19); 13 (10 -16), 3(1 - 4); 2(1 - 3) and 4(3 - 6); 3(2 - 4) = 0.0025, 0.005 and 0.008 respectively.

For both the entire C2V5 region and sub-region C3 the first siblings had significantly longer amino acid lengths relative to the second siblings; 207(201 - 216), 200(198 - 202) and 51(49 - 54), 48(47 - 52); p = 0.005 and 0.007 respectively. However, the opposite was true for the V5 region where the second siblings had much longer amino acid lengths 13(12 - 14), 11(14 - 19); p = 0.0006. After gender stratification no differences were observed regarding amino acid lengths whilst female siblings tended to have a denser glycan shield relative to their male counterparts, 14(11 - 16); 12(10 - 13); p = 0.039. Glycosylation patterns found in siblings had similar patterns to those found in the parents, see **Table 6**.

# 6. Discussion

N-glycosylation is an essential co-translational modification process where a sugar, glycan, is covalently attached to the amide group of asparagine (N) residues [29].The N-linked glycosylation of the HIV-1 env gp120 is one of the most important viral protective mechanisms to overcome in order to develop an effective neutralizing antibody-inducing vaccine. Since several PNGs are relatively constant across HIV-1 subtypes, there is a great deal of interest in developing a carbohydrate based antigen designed to elicit a humoral immune response. Studies have shown a subtype env sequence length dependency following transmission with subtypes A and C significantly shifted towards shorter lengths though untrue for subtype B [14, 20, 30]. Our results are similar to previous subtype A and D heterosexual transmission where trends were observed for HIV-1 env lengths but no significant differences were observed with PNGs [19].

For PTCT, our study observed children being infected with shorter sequences demonstrated by significantly shorter sequences in the second sibling relative to the maternal or paternal sequences which tended to increase with age or disease progression, probably due to immune selection as shown in the first siblings who had significantly longer sequences and PNGs relative to the parents. Our results are suggestive of the fact that a child acquires more or less the same number of PNGs like the mother and these tend to decrease with time or disease progression as evidenced by the presence of the first V4 region PNGs observed amongst the second siblings who were about 14 months old but was absent or lost in 3 out of 4 of the first siblings who were about five years old. This observation may have something to do with functional elements of V4 region which exist solely to facilitate viral escape during the evolving glycan shield [41]. PNGs number differences were also observed in chronic HIV-1 infection [31-33]. Similar to our findings some pediatric HIV-1 env subtype C studies have also demonstrated no clear pattern of change in the number PNGs [34,35]. Mother 567 with the least number of PNGs has since died during beginning of this year suggestive of the fact that loss of PNGs may be associated with advanced disease and probably a risk factor of dying. It would be interesting to correlate PNGs with markers of disease progression.

A consistent feature of families' sequence analysis showed the highest levels of variation within the env gp120, V4 and V5 variable including the C3 regions challenging whether the so-called "constant region" with respect to subtype B is really also a constant one when it comes to subtype C. More so, atypically, our families' HIV-1 subtype C V3 region was relatively constant, again querying the currently common practice of extrapolating subtype B findings to non-subtype B ones. Traditionally, V3 region has been considered a variable domain based on analysis of subtype B sequences. However, the small numbers of clones sequenced may not have been sufficient for statistically sound conclusions. A larger sample size is recommended to substantiate these findings. Interestingly, similar results of a relatively constant subtype C V3 region have been obtained elsewhere [36-39]. Conserved PNGs within the V3 region amongst all family members regardless of age or sex points to

their potentially important functional elements which may function primarily to mask the large number of neutralizing antibody epitopes defined in this region. As previously reported by others, emergence of deletions within the V4 region was also observed among all family members both adults and children [40]. These coupled with amino acid substitutions affected the number and distribution of PNGs resulting in the coexistence within some family members V4 variants each characterized by different amino acid sequences and PNGs patterns. Previous subtype C studies have showed extensive V4 length polymorphism where shorter lengths have been shown to enhance infectivity at the cost of exposing neutralizing epitopes [41].

Some countries including Zimbabwe now seek to institute legislation to hold persons criminally responsible for willfully infecting others with HIV. This law has been unsuccessfully applied as it is very difficult to prove criminal intent on the part of the alleged transmitter and currently there is no supporting forensic evidence to prove directionality of infection. For successful prosecution of willful transmission, ascertaining the association of number of PNGs or the HIV-1 env domain length polymorphism and age of infection may be the first step to provide a line of evidence to that effect, hence the need for bigger studies.

# 7. Conclusions

Highest env gp120 region variation characterised by indels were observed within theC3, V4 and V5 sub-regions. Indels characterized s. Our study supports the observation that HIV-1 env C2V5 sequences and PNGs tend to increase with age and disease progression in children. Though sensitive and should be handled carefully, with respect to C3 and V5 sequence lengths it is tempting to propose a possible male to female and female to male heterosexual transmission events for families 205 and 366 including 375 respectively. Ascertaining the association of PNGs or env sequence length polymorphism and period of infection may be the first step towards a possible line of forensic evidence. Hence bigger studies are warranted to substantiate the authenticity of this potentially useful application.

# 8. Acknowledgements

Acknowledgements are due to Drs. Kurewa NE and Munjoma MW including all the support staff for facilitating sample collection. Many thanks are due to the families who participated in this study. Special mention goes to the Letten Foundation and Professor Letten F Saugstad herself for funding the study.

- B. R. Starcich, B. H. Hahn, G. M. Shaw, P. D. McNeely, S. Modrow, H. Wolf, *et al.*, "Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS," *Cell*, Vol. 45, No. 5, 1986, pp. 637-648
- [2] H. Geyer, C. Holschbach, G. Hunsmann and J. Schneider, "Carbohydrates of Human Immunodeficiency Virus. Structures of Oligosaccharides Linked to the Envelope Glycoprotein 120," *The Journal of Biological Chemistry*, Vol. 263, No. 24, 1988, pp. 11760-11767.
- [3] M. Zhang, B. Gaschen, W. Blay, B. Foley, N. Haigwood, C. Kuiken, *et al.*, "Tracking Global Patterns of N-Linked Glycosylation Site Variation in Highly Variable Viral Glycoproteins: HIV, SIV, and HCV Envelopes and influenza Hemagglutinin," *Glycobiology*, Vol. 14, No. 12, 2004, pp. 1229-1246.
- [4] C. K. Leonard, M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas and T. J. Gregory, "Assignment of Intrachain Disulfide Bonds and Characterization of Potential Glycosylation Sites of the Type 1 Recombinant Human Immunodeficiency Virus Envelope Glycoprotein (gp120) Expressed in Chinese Hamster Ovary Cells," *The Journal of Biological Chemistry*, Vol. 265, No. 18, 1990, pp. 10373-10382.
- [5] P. D. Kwong, R. Wyatt, Q. J. Sattentau, J. Sodroski, W. A. Hendrickson, "Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus," *The Journal of Virology*, Vol. 74, No. 4, 2000, pp. 1961-1972. doi:10.1128/JVI.74.4.1961-1972.2000
- [6] R. Wyatt, P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, *et al.*, "The Antigenic Structure of the HIV gp120 Envelope Glycoprotein," *Nature*, 1998, Vol. 393, No. 6686, pp. 705-711.
- [7] J. J. Skehel, D. J. Stevens, R. S. Daniels, A. R. Douglas, M. Knossow, I. A. Wilson, *et al.*, "A Carbohydrate Side Chain on Hemagglutinins of Hong Kong Influenza Viruses Inhibits Recognition by a Monoclonal Antibody," *Proceedings of the National Academy of Sciences*, Vol. 81, No. 6, 1984, pp. 1779-1783. doi:10.1073/pnas.81.6.1779
- [8] P. Botarelli, B. A. Houlden, N. L. Haigwood, C. Servis, D. Montagna and S. Abrignani, "N-Glycosylation of HIVgp120 May Constrain Recognition by T Lymphocytes," *The Journal of Immunology*, Vol. 147, No. 9, 1991, pp. 3128-3132.
- [9] Cheng-Mayer C., Brown A., Harouse J., Luciw P.A. and Mayer A.J., "Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant *in vivo* by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein that Modify N-Linked Glycosylation," *The Journal of Virology*, Vol. 73, No. 7, 1999, pp. 5294-5300.
- [10] X. Wei, J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, *et al.*, "Antibody Neutralization and Escape by HIV-1," *Nature*, Vol. 422, No. 6929, 2003, pp. 307-312.

doi:10.1128/JVI.00141-06

- [11] M. Sagar, X. Wu, S. Lee and J. Overbaugh, "Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity," *The Journal of Virology*, 2006, Vol. 80, No. 19, pp. 9586-9598.
- [12] E. M. Bunnik, L. Pisas, A. C. van Nuenen and H. Schuitemaker, "Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection," *The Journal of Virology*, Vol. 82 No. 16, 2008, pp. 7932-7941. doi:10.1128/JVI.00757-08
- [13] H. F. Gunthard, S. D. Frost, A. J. Leigh-Brown, C. C. Ignacio, K. Kee, A. S. Perelson, *et al.*, "Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy," *The Journal of Virology*, 1999, Vol. 73, No. 11, pp. 9404-9412
- [14] C. A. Derdeyn, J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, *et al.*, "Envelope-Constrained Neutralization-Sensitive HIV-1 after Heterosexual Transmission," *Science*, 2004, Vol. 303, No. 5666, pp. 2019-2022.
- [15] B. Li, J.M. Decker, R. W. Johnson, F. Bibollet-Ruche, X. Wei, J. Mulenga, *et al.*, "Evidence for Potent Autologous Neutralizing Antibody Titers and Compact Envelopes in Early Infection with Subtype C Human Immunodeficiency Virus Type 1," *The Journal of Virology*, Vol. 80, No. 11, 2006, pp. 5211-5218. doi:10.1128/JVI.00201-06
- [16] J. Irungu, E. P. Go, Y. Zhang, D. S. Dalpathado, H. X. Liao, B. F. Haynes, *et al.*, "Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for Glycopeptide Analysis of a Highly Glycosylated HIV Envelope Glycoprotein," *Journal of the American Society for Mass Spectrometry*, Vol. 19, No. 8, 2008, pp. 1209-1220. doi:10.1016/j.jasms.2008.05.010
- [17] H. Zhang, D. C. Tully, F. G. Hoffmann, J. He, C. Kankasa and C. Wood, "Restricted Genetic Diversity of HIV-1 Subtype C Envelope Glycoprotein from Perinatally Infected Zambian Infants," *PLoS One*, Vol. 5, No. 2, 2010, p. e9294. doi:10.1371/journal.pone.0009294
- [18] M. Alexander, R. Lynch, J. Mulenga, S. Allen, C. A. Derdeyn and E. Hunter, "Donor and Recipient Envs from Heterosexual Human Immunodeficiency Virus Subtype C Transmission Pairs Require High Receptor Levels for Entry," *The Journal of Virology*, Vol. 84, No. 8, 2010, pp. 4100-4104. doi:10.1128/JVI.02068-09
- [19] M. Sagar, O. Laeyendecker, S. Lee, J. Gamiel, M. J. Wawer, R. H. Gray, *et al.*, "Selection of HIV Variants with Signature Genotypic Characteristics during Heterosexual Transmission," *Journal of Infectious Diseases*, Vol. 199, No. 4, 2009, pp. 580-589. <u>doi:10.1086/596557</u>
- [20] Y. Liu, M. E. Curlin, K. Diem, H. Zhao, A. K. Ghosh, H. Zhu, et al., "Env Length and N-Linked Glycosylation Following Transmission of Human Immunodeficiency Virus Type 1 Subtype B Viruses," Virology, Vol. 374, No.

2, 2008, pp. 229-233

- [21] B. Chohan, D. Lang, M. Sagar, B. Korber, L. Lavreys, B. Richardson, *et al.*, "Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels," *The Journal of Virology*, 2005, Vol. 79, No. 10, pp. 6528-6531. doi:10.1128/JVI.79.10.6528-6531.2005
- [22] T. Dieltjens, N. Loots, K. Vereecken, K. Grupping, L. Heyndrickx, E. Bottieau, *et al.*, "HIV Type 1 Subtype A Envelope Genetic Evolution in a Slow Progressing Individual with Consistent Broadly Neutralizing Antibodies," *AIDS Research and Human Retroviruses*, Vol. 25, No. 11, 2009, pp. 1165-1169. <u>doi:10.1089/aid.2008.0161</u>
- [23] Y. Ye, Z. H. Si, J. P. Moore and J. Sodroski, "Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged *in vivo*," *The Journal of Virology*, Vol. 74, No. 24, 2000, pp. 11955-11962. doi:10.1128/JVI.74.24.11955-11962.2000
- [24] Y. Li, M. A. Rey-Cuille and S. L. Hu, "N-Linked Glycosylation in the V3 Region of HIV Type 1 Surface Antigen Modulates Coreceptor Usage in Viral Infection," *AIDS Research and Human Retroviruses*, Vol. 17, No. 16, 2001, pp. 1473-1479. doi:10.1089/08892220152644179
- [25] R. M. Lynch, T. Shen, S. Gnanakaran and C. A. Derdeyn, "Appreciating HIV Type 1 Diversity: Subtype Differences in Env," *AIDS Research and Human Retroviruses*, Vol. 25, No. 3, 2009, pp. 237-248. doi:10.1089/aid.2008.0219
- [26] C. N. Scanlan, J. Offer, N. Zitzmann and R. A. Dwek, "Exploiting the Defensive Sugars of HIV- 1 for Drug and Vaccine Design," *Nature*, Vol. 446, No. 7139, 2007, pp. 1038-1045.
- [27] F. Z. Gumbo, G. Q. Kandawasvika, K. Duri, M. P. Mapingure, N. E. Kurewa, K. Nathoo, *et al.*, "Reduced HIV Transmission at Subsequent Pregnancy in a Resource-Poor Setting," *Tropical Doctor*, Vol. 41, No. 3, 2011, pp. 132-135.
- [28] K. Duri, W. Soko, F. Gumbo, K. Kristiansen, M. Mapingure, B. Stray-Pedersen, *et al.*, "Genotypic Analysis of Human Immunodeficiency Virus Type 1 Env V3 Loop Sequences: Bioinformatics Prediction of Coreceptor Usage among 28 Infected Mother-Infant Pairs in a Drug-Naive Population," *AIDS Research and Human Retroviruses*, Vol. 27, No. 4, 2011, pp. 411-419. doi:10.1089/aid.2010.0142
- [29] R. G. Spiro, "Protein glycosylation: Nature, Distribution, Enzymatic Formation, and Disease Implications of Glycopeptide Bonds," *Glycobiology*, Vol. 12, No. 4, 2002, pp. 43R-56R.
- [30] S. Gnanakaran, D. Lang, M. Daniels, T. Bhattacharya, C. A. Derdeyn and B. Korber, "Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120," *The Journal of Virology*, Vol. 81, No. 9, 2007, pp.

4886-4891. doi:10.1128/JVI.01954-06

- [31] N. Chomont, H. Hocini, G. Gresenguet, C. Brochier, H. Bouhlal, L. Andreoletti, *et al.*, "Early Archives of Genetically-Restricted Proviral DNA in the Female Genital Tract after Heterosexual Transmission of HIV-1," *AIDS*, Vol. 21, No. 2, 2007, pp. 153-162.
- [32] K.S. Kemal, B. Foley, H. Burger, K. Anastos, H. Minkoff, C. Kitchen, *et al.*, "HIV-1 in Genital Tract and Plasma of Women: Compartmentalization of Viral Sequences, Coreceptor Usage, and Glycosylation," *Proceedings of the National Academy of Sciences*, Vol. 100, No. 22, 2003, pp. 12972-12977. doi:10.1073/pnas.2134064100
- [33] S. K. Pillai, B. Good, S. K. Pond, J. K. Wong, M. C. Strain, D. D. Richman, *et al.*, "Semen-Specific Genetic Characteristics of Human Immunodeficiency Virus Type 1 Env," *The Journal of Virology*, Vol. 79, No. 3, 2005, pp. 1734-1742. doi:10.1128/JVI.79.3.1734-1742.2005
- [34] F. Y. Tso, F.G. Hoffmann, D. C. Tully, P. Lemey, R. A. Rasmussen, H. Zhang, *et al.*, "A Comparative Study of HIV-1 Clade C Env Evolution in a Zambian Infant with an Infected Rhesus Macaque during Disease Progression," *AIDS*, Vol. 23, No. 14, 2009, pp. 1817-1828.
- [35] H. Zhang, F. Hoffmann, J. He, X. He and C. Kankasa, J. T. West, *et al.*, "Characterization of HIV-1 Subtype C envelope Glycoproteins from Perinatally Infected Children with Different Courses of Disease," *Retrovirology*, Vol. 3, 2006, p. 73.
- [36] B. T. Korber, K. MacInnes, R. F. Smith and G. Myers, "Mutational Trends in V3 Loop Protein Sequences Observed in Different Genetic Lineages of Human Immunodeficiency Virus Type 1," *The Journal of Virology*, Vol.

68, No. 10, 1994, pp. 6730-6744.

- [37] M. B. Patel, N. G. Hoffman and R. Swanstrom, "Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins," *The Journal of Virology*, Vol. 82, No. 2, 2008, pp. 903-916. doi:10.1128/JVI.01444-07
- [38] R. L. Stanfield, M. K. Gorny, S. Zolla-Pazner and I. A. Wilson, "Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity," *The Journal* of Virology, Vol. 80, No. 12, 2006, pp. 6093-6105. doi:10.1128/JVI.00205-06
- [39] P. B. Gilbert, V. Novitsky and M. Essex, "Covariability of Selected Amino Acid Positions for HIV Type 1 Subtypes C and B," *AIDS Research and Human Retroviruses*, Vol. 21, No. 12, 2005, pp. 1016-1030. doi:10.1089/aid.2005.21.1016
- [40] K. A. Buckley, P. L. Li, A. H. Khimani, R. Hofmann-Lehmann, V. Liska, D. C. Anderson, *et al.*, "Convergent Evolution of SIV Env after Independent Inoculation of Rhesus Macaques with Infectious Proviral DNA," *Virology*, Vol. 312, No. 2, 2003, pp. 470-480.
- [41] S. D. Frost, Y. Liu, S. L. Pond, C. Chappey, T. Wrin, C. J. Petropoulos, *et al.*, "Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Variation And Neutralizing Antibody Responses during Transmission of HIV-1 Subtype B," *The Journal of Virology*, Vol. 79, No. 10, 2005, pp. 6523-6527. doi:10.1128/JVI.79.10.6523-6527.2005